1	4 Subjects taking carbamazepine as monotherapy at baseline or who can be transferred to carbamazepine monotherapy in the two months before the Screening Visit Dose of carbamazepine is within that recommended by the SPC Carbamazepine dose has not been altered during the previous 2 weeks prior to the start|carbamazepine[18,31]|||||||||C0006949|2002|2002|carbamazepine
1	4 Subjects taking carbamazepine as monotherapy at baseline or who can be transferred to carbamazepine monotherapy in the two months before the Screening Visit Dose of carbamazepine is within that recommended by the SPC Carbamazepine dose has not been altered during the previous 2 weeks prior to the start|Carbamazepine[219,232]|||||||2 weeks[279,286]||C0006949|2002|2002|carbamazepine
1	4 Subjects taking carbamazepine as monotherapy at baseline or who can be transferred to carbamazepine monotherapy in the two months before the Screening Visit Dose of carbamazepine is within that recommended by the SPC Carbamazepine dose has not been altered during the previous 2 weeks prior to the start|carbamazepine[88,101]|||||||two months[121,131]||C0006949|2002|2002|carbamazepine
1	4 Subjects taking carbamazepine as monotherapy at baseline or who can be transferred to carbamazepine monotherapy in the two months before the Screening Visit Dose of carbamazepine is within that recommended by the SPC Carbamazepine dose has not been altered during the previous 2 weeks prior to the start|carbamazepine[167,180]|||||||||C0006949|2002|2002|carbamazepine
2	of the Baseline Period or 6 weeks if the Baseline Period is to be shortened due to the availability of a retrospective seizure history The carbamazepine dose is to remain stable throughout the study|carbamazepine[445,458]|||||||6 weeks[332,339]||C0006949|2002|2002|carbamazepine
